Tweet
Add more position at the dip due to market overreaction: REGN,HLTH, ERES
Add more position at the dip due to market overreaction: REGN ($8.7),HLTH($9.86)
Add more position at the dip due to market overreaction: REGN ($8.7),HLTH($9.86)
-
-
www.bellwetherreport.com Report for REGN today. Positive article.
www.bellwetherreport.com Report for REGN today. Positive article.
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc
(NASDAQ:REGN)
Share price as of Friday’s close: $8.62
Share price as of now: $9.00
Change: 4.41%
Volume: 353,024 shares, daily average 425,641
Last time this high: January 4, 2005
52-week high: $10.28
52-week low: $4.61
Regeneron Pharmaceuticals was founded in 1988 by CEO Leonard S. Schleifer, M.D., to develop and commercialize new therapeutic agents to treat unmet medical needs. The company initially focused on treatments for diseases of the nervous system. However in 1995, when P. Roy Vagelos, M.D., joined Regeneron as its Chairman, he encouraged development of the Company’s strength in science and technology in more diverse disease settings, such as cancer, eye disease, rheumatoid arthritis, allergy, and asthma.
Regeneron is developing a series of “Traps,” a new class of product candidate which targets and blocks many of the protein hormones whose over activity seems to contribute to many different diseases. Regeneron has therapeutic candidates in clinical trials for the potential treatment of obesity, rheumatoid arthritis, and cancer. The company also has preclinical programs in asthma, allergies, and other diseases and disorders. Regeneron’s scientists continue to be busy in the laboratory bench, producing exciting discoveries that may lead to additional therapeutic product candidates of the future.
During the first quarter of 2005 Regeneron reported revenue of $16.2 million compared to $62.0 million in the same period pf 2004 due primarily to lower revenues related to their collaboration with sanofi-aventis on the VEGF Trap and their prior collaboration with Novartis on the IL-1 Trap. Collaboration revenue earned from sanofi-aventis and Novartis is comprised of contract research and development revenue and research progress payments. Regeneration reported a net loss of $4.1 million, or $0.07 per share for the first quarter of 2005 compared with a net income of $64.5 million, or $1.17 per basic share.
On May 16, 2005 Regeneron announced positive preliminary results from on going phase 1 open-label, dose-escalation study of the VEGF Trap administered intravenously to patients with advanced cancers.
"The preliminary results of this study reinforce our belief that the VEGF Trap has the potential to become an important drug in the treatment of cancer," noted Dr. Jesse Cedarbaum, Regeneron's Vice President Clinical Affairs. "We are looking forward to advancing our clinical program."
The study was designed to examine the safety, pharmacokinetics, biological activity, and preliminary efficacy of the VEGF Trap when administered intravenously every two weeks to patients with advanced solid tumors. The VEGF Trap was generally well tolerated at the dose levels evaluated, with the most common adverse events during treatment including fatigue, pain, and constipation. No anti-VEGF Trap antibodies have been detected, and the maximum tolerated dose has not yet been reached. Preliminary analyses of tumor blood flow and volume by dynamic contrast-enhanced Magnetic Resonance Imaging (MRI) scans have suggested that the VEGF Trap rapidly induces a tumor vascular response. Preliminary efficacy analysis showed evidence of tumor size reduction and prolonged stable disease in some patients after VEGF Trap treatment as a single-agent. One patient achieved a partial response with disappearance of ascites, two patients had minor responses, and one patient has maintained stable disease for over 11 months to date.
On June 10, 2005 Regeneron announced more positive preliminary results from another pilot, this time on weekly dosing of the Interleukin -1 Trap in patients with CIAS1-associated periodic syndrome (CAPS), a family of auto inflammatory diseases. All four patients enrolled in the study to date experienced a positive response to a subcutaneous loading dose regimen of the IL-1 Trap, including a sizable reduction in daily patient diary scores and acute phase reactant levels. In the ongoing chronic dosing phase of the study, these patients continue to demonstrate a positive response to the IL-1 Trap.
Treatment with the IL-1 Trap led to an immediate clinical and laboratory improvement in all patients," the NIAMS investigators reported. "These results will allow us to further investigate the role of IL-1 blockade in treating patients with CAPS and other inflammatory diseases."
The IL-1 Trap is designed to attach to and neutralize IL-1 in the blood stream before it can attach to cell-surface receptors and generate signals that can trigger disease activity in body tissue. Once attached to the Trap, IL-1 cannot bind to the cell surface receptors and, together with the Trap, is flushed from the body. The IL-1 Trap has a long duration in the body, and can be delivered by weekly injection. On July 5, 2005 the company began the initiation of a clinical program to evaluate the VEGF Trap in certain eye diseases utilizing intravitreal injections in the eye. The trial is being conducted on patients with the neovascular AMD, a degenerative condition that is a major cause of severe vision impairment and blindness in adults over 55. "Blocking VEGF is a validated approach in treating wet AMD, and the VEGF Trap blocks all forms of VEGF-A with extremely high affinity," said Jesse M. Cedarbaum, MD, Vice President of Clinical Affairs at Regeneron. "This trial is another significant step forward in further exploring the potential benefit the VEGF Trap can provide to patients suffering from wet AMD and other eye diseases." So far during the second quarter of 2005 the company has enjoyed a lot of success in the trials of the company’s different product candidates. The company will continue to work and conduct trials on these candidates in hopes that they one day enter the market place. If the company can progress any of these treatments into the actual market place, it would be huge. Many of these candidates have high hopes for the treatment of many serious diseases and so far things are looking good. If this success in the trials keeps up the company should enjoy a very positive 2005.
Written By
Kyle Noddin
Kyle Noddin and the Bellwether Report do not have a vested interest in the companies mentioned aboveComment
-
Regeneron testing therapy for blindness cause July 6th 2005
Regeneron testing therapy for blindness cause July 6th 2005
Times Union
THREE STAR
E1
Copyright (c) 2005 Bell & Howell Information and Learning Company. All rights reserved.
EAST GREENBUSH - Regeneron Pharmaceuticals Inc. has begun testing its VEGF Trap, which it hopes will prevent blindness caused by the "wet" form of age-related macular degeneration, or ARMD.
The disease is a major cause of vision impairment and blindness in adults over age 55.
Regeneron's Phase 1 trial is a dose-escalating study designed to assess the safety and tolerability of VEGF (Vascular Endothelial Growth Factor) Trap in patients. It is one of several clinical studies that must be completed before the drug can be submitted for U.S. Food and Drug Administration approval.
Regeneron, based in Tarrytown, has a research and manufacturing site in East Greenbush.
- Alan Wechsler
TMNN000020050706e1760008k
Hoover's Company Profiles, Copyright(c), 2005, Hoover's, Inc., Austin, Tx
Regeneron isn't the Pentagon, but the firm is fighting some serious enemies. Regeneron Pharmaceuticals develops protein-based drugs used to treat a variety of diseases and conditions, including cancer, asthma, and cardiovascular conditions. The biotechnology firm focuses on discovering and developing neurotrophic factors, proteins required for neurons to survive. Regeneron is developing several drug candidates based on its neurotrophic research. Its lead candidate, AXOKINE, targets obesity but its results in clinical trials have been disappointing so far. The company also is collaborating with Aventis Pharmaceuticals on VEGF Trap as a possible treatment for tumors.Comment
-
Undervalued. Target: $36 UPDATE: Slumping Adobe Shares Could Be Set For Turnaround
Undervalued. Target: $36 UPDATE: Slumping Adobe Shares Could Be Set For Turnaround
518 words
7 July 2005
01:43 pm
Dow Jones News Service
English
(c) 2005 Dow Jones & Company, Inc.
(Updates stock price and adds Department of Justice declining to comment in last paragraph.)
NEW YORK (Dow Jones)--Shares in Adobe Systems Inc. (ADBE) have been in a funk, slumping nearly 20% since the beginning of June, amid concerns about its acquisition of Macromedia Inc. (MACR). But the shares could be in store for a turnaround.
Analysts said the concerns, including over a possible delay of the deal and potential competition obstacles, are overblown and the stock weakness makes for a good time to buy.
Karen Haus, an analyst with WR Hambrecht, recommended buying Adobe shares at current prices, reiterating her $36 price target.
Haus' valuation assumes a premium over other software vendors, but that's "justified in our opinion due to the company's excellent growth prospects and strong competitive positioning," she said in a note. WR Hambrecht didn't report any notable conflicts of interest on its Web site.
Prudential and UBS also issued similar supportive statements about Adobe. Smith Barney, however, recommended investors stay on the sidelines until concerns over a possible delay of the Macromedia deal are cleared up.
Prudential owns shares in Adobe. UBS has a banking relationship with the company. Smith Barney didn't disclose any significant conflicts of interest.
The positive comments helped lift the shares Thursday. They were recently trading at $27.50, up 58 cents, or 2.2%. Still, in early June, the shares were comfortably above $33. Macromedia shares recently were up $1, or 2.8%, at $36.89.
Adobe, which created the ubiquitous portable document format and makes the popular Photoshop design software, gets overwhelmingly high marks from the investment community. Seventeen out of 23 analysts that cover the company rate the stock at a buy or strong buy, according to Thomson Financial.
Its $3.4 billion pairing with Macromedia - the maker of Flash, which facilitates multimedia Internet pages - was considered a great match. The deal will swap 0.69 Adobe shares for every Macromedia share. Following the deal, Adobe plans to buy back $1 billion in stock in order to limit the dilution.
Still, hiccups in the all-stock deal, which have included a refiling of the deal notification, a shareholder lawsuit and a restatement of Macromedia's past earnings, have combined with conservative earnings guidance and a security flaw in an older, limited-release version of Acrobat reader to weigh on investor sentiment.
But analysts say there are a number of upcoming events that could provide a catalyst to a rise in the shares. On Friday, the Department of Justice is expected to respond to the Macromedia deal. On July 20, Macromedia will announce its fiscal first-quarter earnings, and perhaps most importantly, Adobe will provide a midquarter update on Aug. 1.
Adobe reiterated that the Macromedia deal will close in the fall, but declined to comment on its stock move. A spokeswoman for the Department of Justice declined to comment.
Document DJ00000020050707e177000lmComment
-
Valueline Comment on ADBE Timeliness 1:
Valueline Comment on ADBE Timeliness 1:
Adobe Systems has agreed to acquire Macromedia in an all-stock transaction, valued at about $3.4 billion. Adobe will pay .69 of a share for each Macromedia share. The deal, which has been approved by the board of directors of both companies, is still subject to regulatory approval. We expect the transaction to close in the fall. Although the acquisition will probably be slightly accretive to earnings, we are not including these contributions in our results until it is finalized.
The purchase of Macromedia will likely help Adobe expand its product offerings. Adobe's Acrobat program allows Internet users to create simple documents. Most of the customers using this program will likely be interested in purchasing Macromedia's Internet design products. Macromedia has also been making advances in the mobile device marketplace. As such, the combination of the two businesses, which spend a considerable amount on research and development, should create significant opportunities. This should help Adobe to compete against large technology companies planning to enter the Internet and graphics marketplace.
Adobe's results should get a boost from the recent upgrade of its creative suite. In addition to previously released design programs, the enhancements includes new software upgrades. The creative suite should help users consolidate their software purchases, as well as promote Adobe's programs.
The earnings outlook is improving. The company reported strong top- and bottom-line results in the first quarter of 2005 (year ends November 30th). We expect this strength to continue going forward. We are increasing our earnings estimate for 2005 slightly, and are introducing an earnings estimate of $1.25 for 2006. Our figures have been adjusted for a recent 2-for-1 stock split.
These shares are ranked 1 (Highest) for Timeliness. The earnings outlook is bright. In addition, our current projections indicate that these shares offer worthwhile appreciation potential for the next 3 to 5 years. The recent decline in Adobe's stock price probably reflects investors' concern about the upcoming acquisition.
May 27, 2005Comment
-
Two new stocks in my Tech portfolio: ADBE,CSCO. ADBE target $36, CSCO: $25
Two new stocks in my Tech portfolio: ADBE,CSCO. ADBE target $36, CSCO: $25
REGN, HLTH, SCHN, OS, LAZ,RHAT My recent call, all are strong financial background and with great uptrend chart.Comment
-
Big news for LAZ. Another 10.71% stake by Jennison Associates. Reports 10.71% Stake I
Big news for LAZ. Another 10.71% stake by Jennison Associates. Reports 10.71% Stake In Lazard
131 words
8 July 2005
03:19 pm
Dow Jones International News
English
(c) 2005 Dow Jones & Company, Inc.
WASHINGTON (Dow Jones)--Jennison Associates LLC reported a 10.71% stake in Lazard Ltd. (LAZ), according to a Schedule 13G filed Friday with the Securities and Exchange Commission.
Jennison Associates, an investment adviser to several investment companies, insurance accounts and institutional clients, beneficially owns about 4 million Lazard common shares, the filing said.
Prudential Financial Inc. (PRU) indirectly owns 100% of the equity interests of Jennison, so Prudential may also be deemed to beneficially own these Lazard's shares, the filing said.
Jennison Associates reported its stake on a form designated for passive investors, those not seeking to change or influence a company's operations.
-By Denise Jia, Dow Jones Newswires; 202-862-1359; [email protected] [ 08-07-05 2022GMT ]
Document DJI0000020050708e178001hu
So Far, JP Morgan 15%, BOA 15% Prudential 10.71%. These major holder are Banks and Insurance companies, they have their good reason to require so much stake into LAZARD, they know exactly what LAZ's future is. LAZ still under IPO, go buy.
Comment
-
RHAT $16 target by most Analyst. Good Support at $14 level. Will see more appreciat
RHAT $16 target by most Analyst. Good Support at $14 level. Will see more appreciation follow analyst recommend.Comment
-
ERES MDRX HLTH follow RX's deal. I called ERES last Friday @13.5.
ERES MDRX HLTH follow RX's deal. I called ERES last Friday @13.5.
These three health care companies have strong FA with the Baby boomer forecast.Comment
-
SCHN $27, just $1 from my target, will hold till $28 short term. Call from $23. LAZ w
SCHN $27, just $1 from my target, will hold till $28 short term. Call from $23. LAZ will see its IPO price back in several weeks.Comment
-
REGN research update:
REGN research update:
Cancer Vaccine; IL-1 Trap Shows Positive Results in Study of Patients with Inflammatory Disease
233 words
16 July 2005
Obesity, Fitness & Wellness Week
289
English
(c) Copyright 2005 Obesity, Fitness & Wellness Week via NewsRx.com
2005 JUL 16 - (NewsRx.com) -- Regeneron Pharmaceuticals, Inc. announced positive preliminary results from an ongoing pilot study of once-weekly dosing of the Interleukin-1 (IL-1) Trap in patients with CIAS1-associated periodic syndrome (CAPS), a family of autoinflammatory diseases.
All four patients enrolled in the study to date experienced a positive response to a subcutaneous loading dose regimen of the IL-1 Trap, including a sizable reduction in daily patient diary scores and acute phase reactant levels. In the ongoing chronic dosing phase of the study, these patients continue to demonstrate a positive response to the IL-1 Trap.
The study was conducted under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health.
The senior investigators in this study are Raphaela Goldbach-Mansky, M.D., Staff Clinician with NIAMS, and Daniel Kastner, M.D., Ph.D., Chief, Genetics and Genomics Branch with NIAMS. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to the IL-1 Trap in CAPS disorders. Currently, there are no approved therapies for CAPS disorders.
This article was prepared by Obesity, Fitness & Wellness Week editors from staff and other reports. Copyright 2005, Obesity, Fitness & Wellness Week via NewsRx.com.
Document OBWK000020050708e17g00085Comment
-
REGN target $15 with its new research (side effect) on eye disease. FA is ranked abov
REGN target $15 with its new research (side effect) on eye disease. FA is ranked above B+ by valueLine and $25 target by 2008. REGN's cash and profit getting better and better. I am holding several thousand shares of REGN from under $9. Will see over $10 soon.Comment
-
LAZ head to its IPO $25. Target $26.5 in the next couple of weeks. TA looks attractiv
LAZ head to its IPO $25. Target $26.5 in the next couple of weeks. TA looks attractive. SCHN target above $30. OS target $20. ADBE target $30. HLTH target $12-$15Comment
-
Holding ADBE to $30. REGN target $15 and LAZ target $26.5. SOLD SCHN above $27 today.
Holding ADBE to $30. REGN target $15 and LAZ target $26.5. SOLD SCHN above $27 today. Holding OS.Comment
-
THis is why LAZ worth at least $26.5
THis is why LAZ worth at least $26.5
Take a look at this link and you will know why LAZ target is $26.5. However my target is not just based on these analyst opinion, but from FA my model.
Article from WJS:
U.S. deal makers still lead the M&A world
July 14th 2005
AFX Asia
(c) 2005, AFX Asia. All rights reserved.
NEW YORK (XFN-ASIA) - When Chinese oil company CNOOC Ltd. Stunned the markets by making a $18.5 billion bid for Unocal Corp. last month, it didn't lean on China's burgeoning banking industry.
Nor did the company go to any Asian-based firm to advise them on the deal. Instead, like many foreign companies, it sought American-made advice from Goldman Sachs Group Inc. , J.P. Morgan Chase and legal advice from Davis Polk & Wardwell.
As CNOOC's choice suggests, Chinese mergers and acquisitions may be grabbing headlines, but U.S. investment banks continue to be grabbing the fees for advising on deals.
"They have a vast wealth of experience, detailed home country knowledge and are very adroit at hiring people from every country," said James Owers, a Harvard University associate and finance professor at Georgia State University. "When you overlay that with the traditional experience you have competitive advantage."
Indeed, though M&A is up in countries around the world, including Japan, the United Kingdom, Italy, Germany, Spain and Russia, the U.S. market remains the hottest with $593 billion in deals through the first half of the year, up 35%, according to Dealogic.
China's M&A market is actually having a slower year through the first half, down 15% to $23 billion. That puts the People's Republic 11th globally behind countries like Canada, Australia and the Netherlands.
U.S. leaders
Through the first half of 2005, four of the top five global advisers were U.S.-based firms: Morgan Stanley , Goldman Sachs, Merrill Lynch & Co. and J. P. Morgan ranked one through four. Swiss bank UBS placed fifth.
Owers cautions that U.S. banks and sellers such as Unocal may learn a lesson from the late 1980s and early 1990s. At that time, foreign buyers, including many from Japan, bought U.S. assets. The fear about foreign ownership incited nationalism and protectionism, Owers said. But, in the end, the sellers and bankers were the ones who profited.
"If someone offers you more than market price, give them the keys and let them drive it away," Owers said.
Shrinking competition
It was only a few years ago when firms such as Lazard Ltd., Cazenove, and Schroeders were considered top competitors emerging from Europe.
But Lazard booted its European management for U.S. banker Bruce Wasserstein and went public on the New York Stock Exchange. J.P. Morgan bought a 50% stake in Cazenove in 2004 and Schroeders was acquired by Citigroup for $2.2 billion in 2000.
In their place, banks such as HSBC Holdings under John Studzinski, Deutsche Bank , Dresdner Kleinwort Wasserstein and Nomura remain second-tier players with bigger ambitions.
Even in Europe
U.S. banks remain the heavyweights in Europe taking advising roles in the two biggest deals of the year. When Bayerische Hypo Vereinsbank agreed to be acquired by UniCredito Italiano in June for $18.6 billion, J.P. Morgan, Citigroup, and Deutsche Bank advised the target. Merrill Lynch and Goldman advised the buyer.
Likewise when Pernod Richard and Fortune Brands agreed to buy Allied Domecq in April for $17.7 billion, Goldman advised Allied, three U.S. banks advised the buyer with Deutsche Bank, CSFB and BNP Paribas.
That U.S. firms are leading the deals isn't new and isn't likely to change.
"They are aggressive in their strategy," Owers said. "If you're good at something and have a good strategy...you will be dominant."
This story was supplied by MarketWatch. For further information see www. marketwatch.com.
MMMMComment
Comment